Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: A phase Ib study (1604) was conducted to evaluate the safety and efficacy of GS-5829, an oral bromodomain and extraterminal inhibitor, alone and in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). A phase I study (1599) in solid tumors/lymphoma was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Rahul, Starodub, Alexander N., Koh, Brian D., Xing, Guan, Armstrong, Andrew J., Carducci, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475238/
https://www.ncbi.nlm.nih.gov/pubmed/35816286
http://dx.doi.org/10.1158/1078-0432.CCR-22-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475238/
https://www.ncbi.nlm.nih.gov/pubmed/35816286
http://dx.doi.org/10.1158/1078-0432.CCR-22-0175

Ejemplares similares